• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Influence of Polypharmacy on the Effectiveness and Safety of Rivaroxaban versus Warfarin in Patients with Nonvalvular Atrial Fibrillation
ConclusionThis real ‐world study suggests that in the setting of polypharmacy and NVAF, rivaroxaban is an effective and safe alternative to warfarin.This article is protected by copyright. All rights reserved.
Source: Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy - December 31, 2018 Category: Drugs & Pharmacology Authors: Brandon K. Martinez, William L. Baker, Nitesh A. Sood, Thomas J. Bunz, Anna ‐Katharina Meinecke, Daniel Eriksson, Craig I. Coleman Tags: Brief Report Source Type: research

Medication Management of Patients Undergoing Transcatheter Aortic Valve Replacement
This article summarizes key literature supporting the pharmacologic management of patients receiving TAVR. This article is protected by copyright. All rights reserved.
Source: Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy - November 9, 2017 Category: Drugs & Pharmacology Authors: Bethany A. Kalich, J. Erin Ledford, Ian B. Hollis Tags: Review of Therapeutics Source Type: research

Comparison of treatment persistence with dabigatran or rivaroxaban versus vitamin K antagonist oral anticoagulants in atrial fibrillation patients: a competing risk analysis in the French nationwide healthcare databases
ConclusionResults from this nationwide cohort study showed high non‐persistence levels with all OACs and suggest that persistence with both dabigatran and rivaroxaban therapy is not better than persistence with VKA therapy. Hospitalizations for bleeding among non‐persistent patients were unlikely to explain these high non‐persistence rates.This article is protected by copyright. All rights reserved.
Source: Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy - September 1, 2017 Category: Drugs & Pharmacology Authors: G éric Maura, Cécile Billionnet, François Alla, Joshua J. Gagne, Antoine Pariente Tags: Original Research Article Source Type: research

Anticoagulation Bridge Therapy in Patients with Atrial Fibrillation: Recent Updates Providing a Rebalance of Risk and Benefit
This article is protected by copyright. All rights reserved.
Source: Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy - May 5, 2017 Category: Drugs & Pharmacology Authors: Candice L. Garwood, Bianca Korkis, Domenico Grande, Claudia Hanni, Amy Morin, Lynette R. Moser Tags: Review of Therapeutics Source Type: research

Comparison of the Safety and Effectiveness of Apixaban versus Warfarin in Patients with Severe Renal Impairment
ConclusionApixaban appears to be a reasonable alternative to warfarin in patients with severe renal impairment.This article is protected by copyright. All rights reserved.
Source: Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy - December 31, 2016 Category: Drugs & Pharmacology Authors: Brooke E. Stanton, Naomi S. Barasch, Katie B. Tellor Tags: Original Research Article Source Type: research

Predictors of Gastrointestinal Bleeding Among Patients with Atrial Fibrillation After Initiating Dabigatran Therapy
ConclusionThe risk of GI bleeding in patients receiving dabigatran is highly associated with increased age and cardiovascular, renal, and other comorbidities, even after adjusting for other factors. Fewer than 50% of patients restarted an anticoagulant after experiencing a GI bleed. Clinicians should continue to monitor for these risk factors or consider whether alternative therapies may be appropriate.
Source: Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy - May 1, 2015 Category: Drugs & Pharmacology Authors: Julie C. Lauffenburger, Denise H. Rhoney, Joel F. Farley, Anil K. Gehi, Gang Fang Tags: Original Research Article Source Type: research

Recent Advances in the Development of Specific Antidotes for Target‐Specific Oral Anticoagulants
Warfarin, a vitamin K antagonist, has been the only orally available anticoagulant for > 60 years. During the past decade, the U.S. Food and Drug Administration has approved several target‐specific oral anticoagulants (TSOACs) for the prophylaxis and treatment of arterial and venous thromboembolism and stroke prevention in patients with nonvalvular atrial fibrillation. These new agents have several advantages over warfarin including more predictable pharmacokinetics and pharmacodynamics, fewer food and drug interactions, and lack of need for routine coagulation monitoring. However, unlike warfarin, currently no ant...
Source: Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy - February 3, 2015 Category: Drugs & Pharmacology Authors: Yoonsun Mo, Felix K. Yam Tags: Review of Therapeutics Source Type: research

Thrombosis in Continuous‐Flow Left Ventricular Assist Devices: Pathophysiology, Prevention, and Pharmacologic Management
Continuous‐flow left ventricular assist devices reduce short‐term mortality and improve quality of life in patients with end‐stage heart failure. Unfortunately, device‐related complications remain common, with many patients experiencing adverse events within the first year. New literature suggests that rates of device‐related thrombosis may be increasing since 2011, which is particularly troublesome given that this pathology can result in a disabling stroke, organ damage, and death. In 2013, a group of practitioners in the field of mechanical circulatory support published a treatment algorithm based on their expe...
Source: Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy - October 20, 2014 Category: Drugs & Pharmacology Authors: Douglas L. Jennings, Phillip A. Weeks Tags: Review of Therapeutics Source Type: research

Pages: 1  2